CTLA4 and neoplasm: For example, by activating CTLA-4, PD-1, and PD-L1 inhibitory signals, cancer cells can subvert or disarm immune regulatory pathways, leading to increased tumor survival (Ribas and Wolchok, 2018; Tang et al., 2018).